Live Breaking News & Updates on Convalescent plasma

Stay informed with the latest breaking news from Convalescent plasma on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Convalescent plasma and stay connected to the pulse of your community

Host-microbe multiomic profiling reveals age-dependent immune dysregulation associated with COVID-19 immunopathology

Host-microbe multiomic profiling reveals age-dependent immune dysregulation associated with COVID-19 immunopathology
science.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from science.org Daily Mail and Mail on Sunday newspapers.

United-states , Houston , Texas , Oklahoma , Toronto , Ontario , Canada , California , Oklahoma-city , University-of-california-san-francisco , Sydney , New-south-wales

Physician suing Mayo Clinic gets jury trial

"Mayo Clinic faces a free speech lawsuit from Dr. Michael Joyner, alleging retaliation for criticizing the NIH. Trial set for July 2025, per NBC affiliate KTTC.

Minnesota , United-states , Rochester , New-york , Michael-joyner , Mayo-college-of-medicine , National-institutes-of-health , Cnn , New-york-times , Mayo-clinic , National-institutes , Access-program

Despite Dr. Michael Joyner's positive job reviews, Mayo Clinic cites unprofessional behavior

Dr. Michael Joyner is suing Mayo Clinic for disciplinary actions against him for “problematic” statements and “unprofessional” behavior. His job reviews describe him as “a true innovator. Fearless."

New-york , United-states , Virginia , Boston , Massachusetts , Rochester , Andrea-kalmanovitz , R-scott-wright , Elizabeth-cohen , Michael-joyner , Carlos-mantilla , Gianrico-farrugia

Use of covid-19 convalescent plasma to treat patients admitted to hospital for covid-19 with or without underlying immunodeficiency: open label, randomised clinical trial

Objective To evaluate the efficacy of covid-19 convalescent plasma to treat patients admitted to hospital for moderate covid-19 disease with or without underlying immunodeficiency (CORIPLASM trial).

Design Open label, randomised clinical trial.

Setting CORIMUNO-19 cohort (publicly supported platform of open label, randomised controlled trials of immune modulatory drugs in patients admitted to hospital with moderate or severe covid-19 disease) based on 19 university and general hospitals across France, from 16 April 2020 to 21 April 2021.

Participants 120 adults (n=60 in the covid-19 convalescent plasma group, n=60 in the usual care group) admitted to hospital with a positive SARS-CoV2 test result, duration of symptoms <9 days, and World Health Organization score of 4 or 5. 49 patients (n=22, n=27) had underlying immunosuppression.

Interventions Open label randomisation to usual care or four units (200-220 mL/unit, 2 units/day over two consecutive days) of covid-19 convalescent plasma with a seroneutralisation titre >40.

Main outcome measures Primary outcomes were proportion of patients with a WHO Clinical Progression Scale score of ≥6 on the 10 point scale on day 4 (higher values indicate a worse outcome), and survival without assisted ventilation or additional immunomodulatory treatment by day 14. Secondary outcomes were changes in WHO Clinical Progression Scale scores, overall survival, time to discharge, and time to end of dependence on oxygen supply. Predefined subgroups analyses included immunosuppression status, duration of symptoms before randomisation, and use of steroids.

Results 120 patients were recruited and assigned to covid-19 convalescent plasma (n=60) or usual care (n=60), including 22 (covid-19 convalescent plasma) and 27 (usual care) patients who were immunocompromised. 13 (22%) patients who received convalescent plasma had a WHO Clinical Progression Scale score of ≥6 at day 4 versus eight (13%) patients who received usual care (adjusted odds ratio 1.88, 95% credible interval 0.71 to 5.24). By day 14, 19 (31.6%) patients in the convalescent plasma group and 20 (33.3%) patients in the usual care group needed ventilation, additional immunomodulatory treatment, or had died. For cumulative incidence of death, three (5%) patients in the convalescent plasma group and eight (13%) in the usual care group died by day 14 (adjusted hazard ratio 0.40, 95% confidence interval 0.10 to 1.53), and seven (12%) patients in the convalescent plasma group and 12 (20%) in the usual care group by day 28 (adjusted hazard ratio 0.51, 0.20 to 1.32). In a subgroup analysis performed in patients who were immunocompromised, transfusion of covid-19 convalescent plasma was associated with mortality (hazard ratio 0.39, 95% confidence interval 0.14 to 1.10).

Conclusions In this study, covid-19 convalescent plasma did not improve early outcomes in patients with moderate covid-19 disease. The efficacy of convalescent plasma in patients who are immunocompromised should be investigated further.

Trial registration ClinicalTrials.gov [NCT04345991][1].

Data are available upon reasonable request. The data for this article will be made available after publication on request from any qualified researchers or academics. The data include: analysed deidentified participant data, data dictionary, study protocol, statistical analysis plan, and informed consent form, among other data. The data will be shared for two years after publication on receipt of a request sent to raphael.porcher@aphp.fr.

[1]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT04345991&atom=%2Fbmjmed%2F2%2F1%2Fe000427.atom

Paris , France-general- , France , Mauritius , Ile-de-france , French , Association-for-the-advancement-of-blood , International-direction-of-clinical-research , Assistance-publique-h , Convalescent-plasma , Nested-trial

Convalescent plasma reduces mortality by 10% in COVID-19 patients on artificial respiratory assistance: Clinical trial

Convalescent plasma reduces mortality by 10% in COVID-19 patients on artificial respiratory assistance: Clinical trial
medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.

Belgium , Belgian , University-of-li , New-england-journal , Belgian-red-cross , Assistant-professor , Convalescent-plasma , Mechanically-ventilated-patients ,

Study shows benefit of convalescent plasma in Covid-19 patients requiring artificial ventilation

In a study published in The New England Journal of Medicine, clinicians and researchers from the CHU of Liège and the University of Liège show that the administration of plasma taken from convalescent donors after infection with Sars-CoV-2 to patients suffering from acute respiratory distress syndrome requiring artificial mechanical ventilation significantly reduced mortality (10%).

Belgium , Belgian , Megan-craig , University-of-li , New-england-journal , Belgian-red-cross , Convalescent-plasma , Ovid-19 , Ortality , Espiratory , Ospital , Ntensive-care

Managing hospitalized patients with COVID-19 : JAAPA

Managing hospitalized patients with COVID-19 : JAAPA
lww.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lww.com Daily Mail and Mail on Sunday newspapers.

United-states , India , America , Multifactorial-adaptive-platform-trial-for-community , Infectious-diseases-society-of-america , World-health-organization-coronavirus , National-institutes-of-health , National-institutes , Randomized-evaluation , Multifactorial-adaptive-platform-trial , Community-acquired-pneumonia

Early treatment with convalescent plasma may reduce risk of long COVID

Findings from a nationwide, multicenter study led by Johns Hopkins Medicine and the Johns Hopkins Bloomberg School of Public Health suggest that patients with COVID-19 have less chance of developing post-COVID conditions -; commonly known as long COVID -; if they receive early treatment with plasma from convalescent (recovered) COVID patients that contain antibodies against SARS-CoV-2, the virus that causes COVID-19.

United-states , American , Megan-craig , Kelly-gebo , David-sullivan , Aaron-tobian , American-society-for-microbiology , Transfusion-medicine-division , Johns-hopkins-university-school-of-medicine , Johns-hopkins-bloomberg-school-of-public-health , Johns-hopkins-medicine , Johns-hopkins-bloomberg-school

Inflammatory profiles in vaccinated vs. unvaccinated individuals following SARS-CoV-2 infection

A group of researchers determined the impact of vaccination on inflammation levels in individuals infected with SARS-CoV-2.

United-states , Us-department-of-defense , Lancet-microbe , Convalescent-plasma , Hopkins-institutional-review-board , Sars , Ars-cov-2 , Denovirus , Ntibodies , Lood , Onvalescent-plasma

Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial | Critical Care Medicine | JAMA

This randomized trial compares the effects of convalescent plasma therapy with standard care vs standard care alone on time to clinical improvement among patien

China , Hubei , Guangdong , Peking , Beijing , Wuhan , Chengdu , Sichuan , Miami , Florida , United-states , University-of-miami